Bearish
$LJPC their only approved drug is a major flop: sales are only $20M/yr and stagnant. The other one is not approved yet and is for malaria, so for a very poor population. Wake up, there's a reason this 💩 is trading for less than cash. I repeat: less than cash! I've been short since low teens and will be until this files for BK in one year or so.
  • 5